16.11.2012 Views

251 286 - Biotech Bayern

251 286 - Biotech Bayern

251 286 - Biotech Bayern

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

NascaCell Technologies AG<br />

BIOTECH DEVICES & REAGENTS<br />

Keywords: Drug Development, Aptamer Technology, Peptide/Protein<br />

NascaCell Technologies AG is a global leader in the automated production<br />

and marketing of aptamers and Microbodies. Aptamers are small, functional<br />

oligonucleotides binding to target proteins with very high affinities and<br />

specificities. Because of their drug like binding characteristics, aptamers<br />

typically show strong inhibition of protein function. NascaCell selects aptamers<br />

in a rapid, automated procedure. This allows their generation in 8-10 weeks with<br />

proven track record in target validation and drug discovery. Microbodies are<br />

very small (ca 35 amino acids) and extremely stable proteins. Active peptides<br />

can be grafted or new sequences identified with bacterial display.<br />

Microbodies combine the selectivity of biologic agents with the ease of<br />

handling and storage of small molecule drug compounds.<br />

NeuroProfile GmbH<br />

BIOTECH THERAPEUTICS & DIAGNOSTICS<br />

NeuroProfile is committed to the discovery and development of novel therapeutics<br />

for the treatment of Central Nervous System (CNS) diseases. The main<br />

objective is the identification and commercialization of novel neuronal drug<br />

targets (disease-related genes or proteins) for the most important neurodegenerative<br />

diseases Alzheimer and Parkinson and for psychiatric disorders<br />

such as schizophrenia and depression. Our targets will be the basics for forthcoming<br />

drug generations with new mechanisms of action that not only<br />

ameliorate the disease symptoms, but potentially prevent or block progression<br />

of the disease.<br />

Several patent pending target candidates are run in preclinical validation<br />

projects.<br />

NIGU Chemie GmbH<br />

PHARMA & CHEMICAL INDUSTRY<br />

Nigu offers a full range of high-purity guanidine salts for biotechnological<br />

applications, which meet the supreme quality standards set by the biopharmaceutical<br />

industry. The product group includes several grades of guanidine<br />

hydrochloride for separation and purification of recombinant proteins and antibodies.<br />

Guanidine thiocyanate for nucleic acid based diagnostics is another<br />

integral part of the portfolio. A typical example is to provide guanidine-salts<br />

and recycling of used solutions as a complete package to the biopharmaceutical<br />

industry.<br />

Contact:<br />

Dr. Michael Szardenings<br />

Max-Lebsche-Platz 31<br />

3. OG, Modul D<br />

D-81377 München<br />

Phone: +49 (0) 89 54 72 72 10<br />

Fax: +49 (0) 89 54 72 72 22<br />

E-Mail: customer@nascacell.de<br />

Internet: www.nascacell.de<br />

Contact:<br />

Dr. Thomas Rohrmeier<br />

Josef-Engert-Str. 9<br />

D-93053 Regensburg<br />

Phone: +49 (0) 941 7853690<br />

Fax: +49 (0) 941 7853699<br />

E-Mail: info@neuroprofile.com<br />

Internet: www.neuroprofile.com<br />

Contact:<br />

Dr. Frank Fleischer<br />

Beuthener Str. 2<br />

D-84478 Waldkraiburg<br />

Phone: +49 (0) 8638 962-0<br />

Fax: +49 (0) 8638 962-<strong>286</strong><br />

E-Mail: info@nigu.de<br />

Internet: www.nigu.de<br />

89

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!